CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression : A study of fully automated immunoassays in BioFINDER and ADNI cohorts
(2018) In Alzheimer's and Dementia 14(11). p.1470-1481- Abstract
Introduction: We studied whether fully automated Elecsys cerebrospinal fluid (CSF) immunoassay results were concordant with positron emission tomography (PET) and predicted clinical progression, even with cutoffs established in an independent cohort. Methods: Cutoffs for Elecsys amyloid-β1–42 (Aβ), total tau/Aβ(1–42), and phosphorylated tau/Aβ(1–42) were defined against [18F]flutemetamol PET in Swedish BioFINDER (n = 277) and validated against [18F]florbetapir PET in Alzheimer's Disease Neuroimaging Initiative (n = 646). Clinical progression in patients with mild cognitive impairment (n = 619) was studied. Results: CSF total tau/Aβ(1–42) and phosphorylated tau/Aβ(1–42) ratios were highly concordant with... (More)
Introduction: We studied whether fully automated Elecsys cerebrospinal fluid (CSF) immunoassay results were concordant with positron emission tomography (PET) and predicted clinical progression, even with cutoffs established in an independent cohort. Methods: Cutoffs for Elecsys amyloid-β1–42 (Aβ), total tau/Aβ(1–42), and phosphorylated tau/Aβ(1–42) were defined against [18F]flutemetamol PET in Swedish BioFINDER (n = 277) and validated against [18F]florbetapir PET in Alzheimer's Disease Neuroimaging Initiative (n = 646). Clinical progression in patients with mild cognitive impairment (n = 619) was studied. Results: CSF total tau/Aβ(1–42) and phosphorylated tau/Aβ(1–42) ratios were highly concordant with PET classification in BioFINDER (overall percent agreement: 90%; area under the curve: 94%). The CSF biomarker statuses established by predefined cutoffs were highly concordant with PET classification in Alzheimer's Disease Neuroimaging Initiative (overall percent agreement: 89%–90%; area under the curves: 96%) and predicted greater 2-year clinical decline in patients with mild cognitive impairment. Strikingly, tau/Aβ ratios were as accurate as semiquantitative PET image assessment in predicting visual read–based outcomes. Discussion: Elecsys CSF biomarker assays may provide reliable alternatives to PET in Alzheimer's disease diagnosis.
(Less)
- author
- author collaboration
- organization
- publishing date
- 2018-11
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Amyloid PET concordance, Amyloid-β (1–42), Biomarker validation, Clinical progression, CSF biomarkers, Cutoffs, Phosphorylated tau (pTau), Total tau (tTau)
- in
- Alzheimer's and Dementia
- volume
- 14
- issue
- 11
- pages
- 1470 - 1481
- publisher
- Wiley
- external identifiers
-
- pmid:29499171
- scopus:85044290649
- ISSN
- 1552-5260
- DOI
- 10.1016/j.jalz.2018.01.010
- language
- English
- LU publication?
- yes
- id
- 9d721213-1523-4d6d-b249-6fa9025688b8
- date added to LUP
- 2018-04-09 14:28:29
- date last changed
- 2024-04-15 06:01:09
@article{9d721213-1523-4d6d-b249-6fa9025688b8, abstract = {{<p>Introduction: We studied whether fully automated Elecsys cerebrospinal fluid (CSF) immunoassay results were concordant with positron emission tomography (PET) and predicted clinical progression, even with cutoffs established in an independent cohort. Methods: Cutoffs for Elecsys amyloid-β<sub>1–42</sub> (Aβ), total tau/Aβ(1–42), and phosphorylated tau/Aβ(1–42) were defined against [<sup>18</sup>F]flutemetamol PET in Swedish BioFINDER (n = 277) and validated against [<sup>18</sup>F]florbetapir PET in Alzheimer's Disease Neuroimaging Initiative (n = 646). Clinical progression in patients with mild cognitive impairment (n = 619) was studied. Results: CSF total tau/Aβ(1–42) and phosphorylated tau/Aβ(1–42) ratios were highly concordant with PET classification in BioFINDER (overall percent agreement: 90%; area under the curve: 94%). The CSF biomarker statuses established by predefined cutoffs were highly concordant with PET classification in Alzheimer's Disease Neuroimaging Initiative (overall percent agreement: 89%–90%; area under the curves: 96%) and predicted greater 2-year clinical decline in patients with mild cognitive impairment. Strikingly, tau/Aβ ratios were as accurate as semiquantitative PET image assessment in predicting visual read–based outcomes. Discussion: Elecsys CSF biomarker assays may provide reliable alternatives to PET in Alzheimer's disease diagnosis.</p>}}, author = {{Hansson, Oskar and Seibyl, John and Stomrud, Erik and Zetterberg, Henrik and Trojanowski, John Q. and Bittner, Tobias and Lifke, Valeria and Corradini, Veronika and Eichenlaub, Udo and Batrla, Richard and Buck, Katharina and Zink, Katharina and Rabe, Christina and Blennow, Kaj and Shaw, Leslie M.}}, issn = {{1552-5260}}, keywords = {{Amyloid PET concordance; Amyloid-β (1–42); Biomarker validation; Clinical progression; CSF biomarkers; Cutoffs; Phosphorylated tau (pTau); Total tau (tTau)}}, language = {{eng}}, number = {{11}}, pages = {{1470--1481}}, publisher = {{Wiley}}, series = {{Alzheimer's and Dementia}}, title = {{CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression : A study of fully automated immunoassays in BioFINDER and ADNI cohorts}}, url = {{http://dx.doi.org/10.1016/j.jalz.2018.01.010}}, doi = {{10.1016/j.jalz.2018.01.010}}, volume = {{14}}, year = {{2018}}, }